Drugs / TKC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04990063 | Aug 2021 → Aug 2022 | non-small cell lung carcinoma | suhaichuan | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TKC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990063 ↗ |
| Modality | Cell therapy | “Tumor killer cells (TKC) are mixed cultures of two kinds of innate immune cells, namely natural killer cells (NK cells) and gamma delta T cells (γδT cells), which are...” NCT04990063 ↗ |